Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:DSGN NASDAQ:GLUE NASDAQ:IGMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.50-16.9%$1.26$0.77▼$5.80$363.37M0.7611.02 million shs29.93 million shsDSGNDesign Therapeutics$5.77+4.3%$4.36$2.60▼$7.77$328.59M1.61135,634 shs87,280 shsGLUEMonte Rosa Therapeutics$4.90+2.0%$4.94$3.50▼$12.40$301.08M1.42589,334 shs355,190 shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth0.00%+25.00%+71.43%+48.76%-65.45%DSGNDesign Therapeutics0.00%+6.35%+44.76%+37.91%+16.42%GLUEMonte Rosa Therapeutics0.00%+4.58%+0.21%+3.45%-22.20%IGMSIGM Biosciences0.00%0.00%-3.05%+1.60%-87.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth1.1129 of 5 stars0.04.00.00.03.20.81.3DSGNDesign Therapeutics0.1503 of 5 stars0.00.00.00.02.32.50.0GLUEMonte Rosa Therapeutics2.689 of 5 stars3.31.00.00.02.71.71.9IGMSIGM Biosciences4.5406 of 5 stars3.03.00.04.63.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.33SellN/AN/ADSGNDesign Therapeutics 0.00N/AN/AN/AGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33213.24% UpsideIGMSIGM Biosciences 1.90Reduce$5.50333.07% UpsideCurrent Analyst Ratings BreakdownLatest IGMS, CGC, DSGN, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M1.59N/AN/A$1.90 per share0.79DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AGLUEMonte Rosa Therapeutics$177.99M1.70N/AN/A$3.63 per share1.35IGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.3613.54N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)IGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)Latest IGMS, CGC, DSGN, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/A8/7/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.593.072.12DSGNDesign TherapeuticsN/A25.1325.13GLUEMonte Rosa TherapeuticsN/A7.167.16IGMSIGM BiosciencesN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%DSGNDesign Therapeutics56.64%GLUEMonte Rosa Therapeutics79.96%IGMSIGM Biosciences42.79%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%DSGNDesign Therapeutics23.50%GLUEMonte Rosa Therapeutics6.50%IGMSIGM Biosciences57.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableGLUEMonte Rosa Therapeutics9061.76 million57.75 millionOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableIGMS, CGC, DSGN, and GLUE HeadlinesRecent News About These CompaniesWall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to HoldAugust 17, 2025 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by AnalystsAugust 15, 2025 | marketbeat.comIGM Biosciences (IGMS) Expected to Announce Earnings on WednesdayAugust 7, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Announces Earnings ResultsAugust 2, 2025 | marketbeat.comIGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass EstimatesJuly 31, 2025 | zacks.comIGM Biosciences, Inc. (NASDAQ:IGMS) CFO Sells $11,101.07 in StockJuly 26, 2025 | insidertrades.comIGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - NasdaqJuly 3, 2025 | nasdaq.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 3, 2025 | seekingalpha.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders - MorningstarJuly 3, 2025 | morningstar.comMIGM Biosciences to be acquired by ConcentraJuly 2, 2025 | thepharmaletter.comTConcentra acquires IGM Biosciences, continuing M&A streak with struggling biotechsJuly 2, 2025 | fiercebiotech.comFIGM Biosciences Shares Surge on Takeover Agreement with ConcentraJuly 2, 2025 | msn.comIGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to ShareholdersJuly 1, 2025 | businesswire.comIGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value RightJuly 1, 2025 | globenewswire.comIGM Biosciences Terminates Headquarters Lease AgreementMay 29, 2025 | tipranks.comIGM Biosciences earnings missed by $0.51, revenue fell short of estimatesMay 24, 2025 | investing.comIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comIGM Biosciences ends agreement with SanofiMay 10, 2025 | investing.comIGM Biosciences says it is dropping development of imvotamabMay 10, 2025 | thepharmaletter.comTWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 6.85%April 24, 2025 | aaii.comAWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 5.91%April 17, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGMS, CGC, DSGN, and GLUE Company DescriptionsCanopy Growth NASDAQ:CGC$1.50 -0.31 (-16.94%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Design Therapeutics NASDAQ:DSGN$5.77 +0.24 (+4.34%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Monte Rosa Therapeutics NASDAQ:GLUE$4.89 +0.10 (+1.98%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.IGM Biosciences NASDAQ:IGMS$1.27 0.00 (0.00%) As of 08/14/2025IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
